NASDAQ$TBPH
Theravance Biopharma Inc · Q4 2024 earnings
Q4 2024 earnings · · After market close · Investor relations
Briefing
Theravance Biopharma, Inc. reported record fourth quarter and full year 2024 financial results, driven by strong YUPELRI sales and a significant TRELEGY milestone.
Theravance Biopharma concluded 2024 with record fourth quarter YUPELRI net sales and profitability, achieving a $50 million TRELEGY related sales milestone. The company also made steady progress in its CYPRESS study and ended the quarter with $88 million in cash.
- YUPELRI® (revefenacin) US net sales reached an all-time high of $66.7 million in Q4 2024, a 10% increase year-over-year.
- FY 2024 TRELEGY Net Sales, as reported by GSK, were $3.46 billion, triggering a $50 million milestone payment to Theravance Biopharma.
- The CYPRESS study for Ampreloxetine is on track to enroll the final patient in the open label portion by mid-2025.
- The company ended Q4 2024 with $88 million in cash, excluding the $50 million TRELEGY milestone received in February 2025.
Headline financials
Revenue & EPS history
Theravance · Revenue · Quarterly
$18.8M
Revenue by segment
Theravance · $19.4K total across 1 segment · Q3 2022
- YUPELRI$19.4K—100.0%
Forward guidance
Theravance Biopharma expects minimal levels of Non-GAAP Losses from Operations and Cash Burn in 2025, similar to 2024 levels, with R&D expenses between $32 million and $38 million and SG&A expenses between $50 million and $60 million, excluding share-based compensation.
Tailwinds
- Expects minimal Non-GAAP Losses from Operations and Cash Burn in 2025.
- Anticipates full year 2025 R&D expense between $32 million to $38 million (excluding share-based compensation).
- Anticipates full year 2025 SG&A expense between $50 million to $60 million (excluding share-based compensation).
- Expects full year share-based compensation expense between $18 million to $20 million.
- CYPRESS study on track to enroll final patient in the open label portion by mid-2025.
Headwinds
- No specific negative guidance points were provided in the report, but the company expects to incur losses from operations.
- The company's financial guidance for 2025 indicates continued operational expenses.
- The company is undergoing a strategic review, which may introduce uncertainty.
- Future milestone and royalty payments are contingent on sales performance and other factors.
- The company's ability to achieve its financial targets depends on various risks and uncertainties outlined in the forward-looking statements.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2024
-0.4%
Avg return
Earnings day
+1.0%
Avg return
5 days after
+0.5%
Avg return
30 days after
53%
26 / 49 earnings
Positive
+22.6%
Q3 2025
Best reaction
-20.0%
Q2 2017
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | +2.9% | +2.0% | — | |
| Q1 2026 | +0.4% | -2.8% | -3.8% | |
| Q3 2025 | +22.6% | +15.3% | +17.2% | |
| Q2 2025 | +4.2% | +14.2% | +20.0% | |
| Q1 2025 | -9.0% | -15.1% | +13.6% | |
| Q4 2024 | +2.1% | +0.2% | +1.7% | |
| Q3 2024 | +6.6% | +4.8% | +8.7% | |
| Q2 2024 | -18.8% | -20.5% | -16.6% | |
| Q1 2024 | +0.1% | -1.0% | -7.9% | |
| Q4 2023 | +7.9% | +5.1% | +0.3% | |
| Q3 2023 | +2.8% | +1.3% | +6.3% | |
| Q2 2023 | -2.1% | +0.2% | -4.0% | |
| Q1 2023 | +0.4% | -0.3% | -1.4% | |
| Q4 2022 | +9.4% | +2.0% | +8.6% | |
| Q3 2022 | +4.0% | +13.2% | +7.4% | |
| Q2 2022 | -5.4% | -2.6% | +1.4% | |
| Q1 2022 | -9.5% | -10.5% | -12.0% | |
| Q4 2021 | +6.3% | +7.8% | +4.0% | |
| Q3 2021 | +7.1% | +12.7% | -2.1% | |
| Q2 2021 | -5.9% | -5.9% | -36.4% | |
| Q1 2021 | -1.5% | -0.6% | -15.6% | |
| Q4 2020 | -3.3% | -8.4% | +10.7% | |
| Q3 2020 | -13.4% | -3.6% | -12.0% | |
| Q2 2020 | -11.9% | -15.8% | -15.8% | |
| Q1 2020 | -2.5% | +3.8% | -6.7% | |
| Q4 2019 | -10.5% | +0.6% | +0.7% | |
| Q3 2019 | +0.9% | +3.3% | +23.3% | |
| Q2 2019 | +6.4% | -0.1% | +10.8% | |
| Q1 2019 | -11.8% | -12.8% | -37.8% | |
| Q4 2018 | +1.0% | -0.5% | -7.0% | |
| Q3 2018 | -1.5% | +7.5% | +14.1% | |
| Q2 2018 | +17.3% | +20.3% | +21.0% | |
| Q1 2018 | +5.4% | +7.2% | +1.1% | |
| Q4 2017 | -8.4% | +0.7% | -15.7% | |
| Q3 2017 | -4.3% | -0.7% | -10.6% | |
| Q2 2017 | -20.0% | -19.3% | +3.8% | |
| Q1 2017 | +1.5% | -4.6% | -3.4% | |
| Q4 2016 | +1.0% | +5.9% | +22.2% | |
| Q3 2016 | +17.6% | +32.1% | +17.6% | |
| Q2 2016 | +3.0% | +6.2% | +15.6% | |
| Q1 2016 | +5.1% | — | — | |
| Q4 2015 | -0.3% | — | — | |
| Q3 2015 | -1.5% | — | — | |
| Q2 2015 | +0.4% | — | — | |
| Q1 2015 | +3.0% | — | — | |
| Q4 2014 | -6.9% | — | — | |
| Q3 2014 | -1.9% | — | — | |
| Q2 2014 | -7.5% | — | — | |
| Q1 2014 | -2.6% | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q4 2012 | — | — | — | |
| Q3 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro